Silo Pharma Initiate Toxicity Study of Ketamine Formulation for Fibromyalgia Treatment
Silo Pharma (Nasdaq: SILO), a developmental-stage psychedelic biopharmaceutical firm, announced today that it has begun a preclinical toxicity study of its novel time-released, dosage-controlled ketamine formulation, designated as SP-26, for the treatment of fibromyalgia. About Silo Pharma Silo Pharma is a biotechnology startup that wants to combine conventional medications with psychedelic research for people suffering from conditions like post-traumatic stress disorder (PTSD), Alzheimer’s disease, and other rare neurological diseases. Silo aims to discover assets that can be licensed and financed so that important research may be done, which the company believes will benefit patients and the healthcare sector. Silo Pharma The post Silo Pharma Initiate Toxicity Study of Ketamine Formulation for Fibromyalgia Treatment appeared first on Psychedelic Chronicle.
External link. We are not responsible for the content.
Read more ↗More From Psychedelic Chronicle
Choose Ketamine Complete Capital Raise to Expand Technology Platform
In a major milestone for mental health care, Austin-based Choose Your Horizon Inc., also known as Choose Ketamine, ha...
Biomind Labs Secure FDA Pre-IND Meeting for Feedback on NCE Triptax
The well-known psychedelic biotech company Biomind Labs Inc. (NEO: BMND) (OTC: BMNDF) (FSE: 3XI) announced that it ha...
Numinus Develop Psilocybin Mushroom Tea Bags for Psychedelic Research Use
Numinus Wellness Inc.’s (OTCQX: NUMIF) (TSX: NUMI) research division, Numinus Bioscience, recently announced the deve...
Latest News
Comment perfectionner la préparation de son trip ?
La préparation d’un voyage est un processus à la fois intérieur et extérieur – qui consiste à aligner l’intention, l’...
Authors of Largest Microdosing Study Suggest Benefits Limited To Dosing Day
Recent research surveying 1,435 microdosers suggests that microdosing’s duration of effect might be more like that of...
The FDA is changing the drug approval process; In a Senate hearing, Surgeon General nominee Casey Means was asked about psychedelics use
Plus: RAND survey shows that nearly a quarter of U.S. adults support legal use of psilocybin mushrooms; Reunion Neuro...
Psilocybin for OCD: Terence Ching on Lessons from Yale’s Randomised Trials
In this conversation with Psychedelic Alpha’s Josh Hardman, Dr. Terence Ching discusses his journey into the field an...
Can Psychedelics Break the Consumption Cycle?
Consumer culture doesn’t just shape what we buy — it shapes what we want. Here’s why that’s harder to escape than you...
Psychedelics Can Just Be for Fun
Welcome to the Psychedelic Blog. I write about the impact of Psychedelics on Grieving, Relationships, Culture & Death.